Tocqueville Asset Management’s GSK GSK Stock Holding History

Tocqueville Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.6M	Buy	49,557 +12,800	+35%	+$677K	0.03%	282
2026 Q1	$2.03M	Sell	36,757 -10,112	-22%	-$548K	0.03%	288
2025 Q4	$2.3M	Buy	46,869 +112	+0.2%	+$5.22K	0.03%	292
2025 Q3	$2.02M	Hold	46,757	–	–	0.03%	300
2025 Q2	$1.8M	Sell	46,757 -143	-0.3%	-$5.46K	0.03%	297
2025 Q1	$1.82M	Hold	46,900	–	–	0.03%	280
2024 Q4	$1.59M	Buy	46,900 +8,950	+24%	+$322K	0.02%	307
2024 Q3	$1.55M	Hold	37,950	–	–	0.02%	297
2024 Q2	$1.46M	Hold	37,950	–	–	0.02%	301
2024 Q1	$1.63M	Sell	37,950 -3,700	-9%	-$153K	0.03%	296
2023 Q4	$1.54M	Sell	41,650 -9,150	-18%	-$328K	0.03%	288
2023 Q3	$1.84M	Buy	50,800 +23,700	+87%	+$841K	0.04%	261
2023 Q2	$966K	Buy	+27,100	New	+$972K	0.02%	348
2017 Q3	–	Sell	-10,320	Closed	-$556K	–	822
2017 Q2	$556K	Sell	10,320 -1,215	-11%	-$64.8K	0.01%	579
2017 Q1	$608K	Sell	11,535 -1,250	-10%	-$63.4K	0.01%	552
2016 Q4	$615K	Sell	12,785 -337,164	-96%	-$16.7M	0.01%	562
2016 Q3	$18.9M	Buy	349,949 +12,528	+4%	+$687K	0.23%	117
2016 Q2	$18.3M	Buy	337,421 +23,107	+7%	+$1.22M	0.22%	112
2016 Q1	$15.9M	Buy	314,314 +20,426	+7%	+$1.02M	0.21%	129
2015 Q4	$14.8M	Buy	293,888 +11,774	+4%	+$600K	0.2%	139
2015 Q3	$13.6M	Buy	282,114 +271,230	+2,492%	+$14.1M	0.18%	159
2015 Q2	$567K	Sell	10,884 -204	-2%	-$11.5K	0.01%	683
2015 Q1	$640K	Buy	11,088 +410	+4%	+$23.5K	0.01%	662
2014 Q4	$570K	Sell	10,678 -788	-7%	-$44.1K	0.01%	680
2014 Q3	$659K	Sell	11,466 -22,452	-66%	-$1.38M	0.01%	567
2014 Q2	$2.27M	Buy	+33,918	New	+$2.3M	0.02%	462
2013 Q4	–	Sell	-19,900	Closed	-$1.25M	–	1381
2013 Q3	$1.25M	Sell	19,900 -400	-2%	-$25.7K	0.02%	488
2013 Q2	$1.27M	Buy	+20,300	New	+$1.29M	0.02%	469

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Tocqueville Asset Management's GSK Position: Q2 2026 in Review

Tocqueville Asset Management increased its GSK (GSK) stake by 35% in Q2 2026, buying an estimated $677K and bringing the position to 49,557 shares worth $2.6M. The position accounts for 0.03% of the portfolio, ranked #282.

Tocqueville Asset Management first reported a position in GSK in Q2 2013 and has held it in 28 quarters since. The position peaked at $18.9M in Q3 2016. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Tocqueville Asset Management held 49,557 shares of GSK worth $2.6M as of Q2 2026.
Tocqueville Asset Management bought 12,800 GSK shares in Q2 2026, an estimated $677K.
GSK made up 0.03% of Tocqueville Asset Management's portfolio in Q2 2026, its #282 holding.
Tocqueville Asset Management first reported a position in GSK in Q2 2013 and has held it in 28 quarters since.
Tocqueville Asset Management's GSK position peaked at $18.9M in Q3 2016.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Tocqueville Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.